Showing results (151-160 of 180) with videos related to

Sort By:
Pageof 18
Frontiers in Oncology|August 12, 2021
Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET StudyEloisa Jantus-Lewintre, Bartomeu Massutí Sureda, José Luis González Larriba, et al.
JAMA Oncology|April 10, 2020
Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST StudyMaria Gonzalez-Cao, Teresa Morán, Judith Dalmau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2026
Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung CancerMariano Provencio, Roberto Serna-Blasco, Ernest Nadal, et al.
International Journal of Radiation Oncology, Biology, Physics|April 21, 2012
Upregulation of trefoil factor 3 (TFF3) after rectal cancer chemoradiotherapy is an adverse prognostic factor and a potential therapeutic targetEnrique Casado, Victor Moreno Garcia, Jose Javier Sánchez, et al.
Scientific Reports|May 18, 2024
Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient managementRocío Rosas-Alonso, Julian Colmenarejo-Fernández, Olga Pernía, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARDSarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Journal for Immunotherapy of Cancer|August 27, 2021
Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trialBelén Sierra-Rodero, Alberto Cruz-Bermúdez, Ernest Nadal, et al.
Journal for Immunotherapy of Cancer|September 28, 2022
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapyMarta Casarrubios, Mariano Provencio, Ernest Nadal, et al.
Cancer Treatment and Research Communications|March 28, 2025
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in SpainAntonio Calles, Mirian Alonso, Paloma Martín-Martorell, et al.
Expert Opinion on Biological Therapy|May 20, 2026
Arian protocol: a phase iii study of sacituzumab and zimberelimab for the treatment of patients with non-small cell lung cancerMariano Provencio, David Aguiar, Mónica Antoñanzas, et al.
Pageof 18